简介内容:Nrf2-IN-3 (Compound R16), a Nrf2 inhibitor, binds to KEAP1 mutants (G333C mKEAP1) thereby restoring the impaired KEAP1/NRF2 interactions. This restoration sensitizes KEAP1-mutant cancer cells to chemotherapeutic agents, such as Cisplatin and Gefitinib, by reestablishing the functionality of the mKEAP1/NRF2 complex [1].